NE: Research funding: Beigene; Speakers Bureau for Beigene, Incyte, and Novartis; Honoraria/consulting/ad boards for Merck, ADC Therapeutics, Ipsen, Lilly, and Novartis N.N.S reports consultancy or advisory committee participation with Miltenyi Biotec, Lilly Oncology, BMS/Juno, Galapagos, Gilead/Kite, Abbvie, Incyte, Seattle Genetics. He has research funding from both Miltenyi Biotec and Lilly Oncology and is on the scientific advisory board for Tundra Therapeutics. HS: Advisory Boards: ADC Therapeutics, Seagen, AbbVie DMS: has received consulting fees from Abbvie, AstraZeneca, Beigene, BMS, Celgene, Eli Lilly, Genentech, Janssen. DMS has received institutional research funding from AstraZeneca, Novartis. CJL: Research Funding from Incyte Corp; Consulting fees from Incyte Corp, Sanofi, Fresenius Kabi; Advisory Boards for Kite Pharma, BMS, Incyte Corp, Kadmon, Sanofi; Speaker Panel: Kite Pharma; Clinical Trial Steering Committee from Incyte Corp. TAO: Research funding from Loxo Oncology. Consulting fees and research funding from ONO Pharmaceuticals. Consulting fees from ADC therapeutics. GS: Advisory boards: Kite, Beigene, Astra Zeneca; Speakers Bureau: Kite, Beigene AVD has received consulting fees from Abbvie, AstraZeneca, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Janssen, Lilly Oncology, MEI Pharma, Merck, Nurix and Prelude and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Beigene, Bristol Meyers Squibb, Cyclacel, GenMab, Lilly Oncology, MEI Pharma, Morphosys and Nurix. PT: Consultancy: TG Therapeutics, ADC Therapeutics, Genentech, GenMab, Seagen and Lilly Oncology HH: Consultancy/ ad boards: Janssen, BMS, GSK; Speakers Bureau: Karyopharm, GSK, Janssen, Amgen SKB: Honoraria: Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, Seagen JBC: Consultant/Advisor: Astra Zeneca, Abbvie, BeiGene, Janssen, Loxo/Lilly, Kite/Gilead, ADCT; Research Funding: LLS, Genentech, AstraZeneca, Novartis, Loxo/Lilly, BMS/Celgene ASK: Research funding from AstraZeneca and BeiGene. Advisory boards for AstraZeneca, Abbvie, BeiGene, Bristol-Myers Squibb, Janssen, Kite a Gilead Company, Lox@Lilly. Speakers bureau for BeiGene. JR: Research funding: Merck, Corvus Pharmaceuticals, Kymera Therapeutics; Consulting: Acrotech biopharma, Kyowa Kirin. JNW: Research funding and honoraria from Merck; Research funding to spouse from Cellectis, Daiichi Sankyo, Rafael, Forty Seven/Gilead, Astellas; Research funding and consultancy fees to spouse from Novartis; Consultancy fees to spouse from Astellas, Ariad/Takeda, CVS/Caremark, Curis, Jazz Pharmaceuticals, King Biotherapeutics, and Rigel Pharmaceuticals. SM: Research funding: Abbvie, AstraZeneca, BeiGene, Janssen, Juno, Loxo, TG Therapeutics. Speakers Bureau: AstraZeneca, BeiGene, Lilly. Advisory boards: Abbvie, AstraZeneca, BMS, Genentech, Janssen SA: Research support to institution for clinical trials from Nektar, Merck, Xencor, Chimagen and Genmab, has membership on Chimagen scientific advisory committee, she serves on Data Safety Monitoring Board for Myeloid Therapeutics; she is a consultant for ADC therapeutics, KITE/Gilead RK: Advisory Board: BMS, Gilead Sciences./Kite Pharma, Janssen, Karyopharm, Pharmacyclics, Morphosys, Epizyme, Genentech/Roche, EUSA, Calithera; Grants/Research Support: BMS, Takeda, BeiGene, Gilead Sciences/Kite, Calithera. Speakers Bureau: AstraZeneca, BeiGene, Morphosys

The study was approved by the institutional review boards at all participating sites and was conducted in compliance with the Declaration of Helsinki.